Cygnus Technologies, LLC
Johnathan Locklear is an experienced professional currently serving as Senior Manager of Tech Support & Assay Development at Cygnus Technologies, LLC since May 2011. In this role, Johnathan acts as a Subject Matter Expert for technical support interactions and leads the development and qualification of custom impurity assays while supervising laboratory staff. Previous positions held at Cygnus include Technical Services Manager, R&D Scientist I, Research and Development Project Scientist, Research and Development Scientist, and Production Technician, where responsibilities ranged from managing interdepartmental interactions to developing custom ELISA assays for clients. Prior to Cygnus, Johnathan was a Student Researcher in both the RISE Fellow program and the NC Space Grant at the University of North Carolina at Pembroke, focusing on endocannabinoid drugs and the effects of gravity on microorganisms, respectively. Educational credentials include a Bachelor of Science in Biotechnology from the University of North Carolina at Pembroke and ongoing studies for a Master of Science in Biotechnology, Regulatory Affairs at the University of Maryland Global Campus.
Cygnus Technologies, LLC
Cygnus Technologies, part of Maravai LifeSciences, is the biopharmaceutical industry’s partner in host cell protein (HCP) and other process-related impurity detection and analytics. In addition, Cygnus now provides innovative viral clearance solutions as well. Cygnus helps companies developing therapeutic proteins, vaccines, antibodies, plasma derivatives and gene therapies to ensure the safety of biotherapeutics prior to human trials, regulatory approval and commercial release. Cygnus provides analytical tools and solutions delivering insights to improve bioprocess development for faster regulatory approval and better clinical outcomes. Cygnus is an industry pioneer responsible for developing and commercializing the first generic assay kits for HCP detection. Its reputation for quality is recognized by the industry and global regulatory agencies. It continues to advance the science of bioprocess impurity detection with new breakthroughs, including its Antibody Affinity Extraction™ (AAE) technology and orthogonal methods of HCP analysis that integrate Mass Spectrometry, AAE and ELISA. To reduce the cost and risk associated with viral clearance studies, Cygnus also offers a unique approach that utilizes non-infectious mock virus particles through its MockV™ virus clearance kits. Cygnus’ proprietary technology, available through its off-the-shelf and custom analytics programs, sets the gold standard for enabling HCP and other bioprocess impurity antibody assays. Cygnus delivers best-in-class customer service and technical expertise, operational excellence and ISO-9001:2015 certified quality management systems. Founded by Ken Hoffman in 1997, Cygnus continues to support and advance technology in order to improve biotherapeutic safety and accelerate the movement of new therapeutics through the development and regulatory approval process. Located in Southport, North Carolina, Cygnus Technologies is online at www.cygnustechnologies.com.